BioCentury
ARTICLE | Company News

Introgen, Rhone-Poulenc Rorer deal

April 15, 2013 7:00 AM UTC

Introgen received a $5 million time-based equity investment from RPR under the terms of its collaboration with RPR GenCell for development of p53 tumor suppressor gene therapy. GenCell will begin Phas...